Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Azacitidine/cedazuridine - Astex Pharmaceuticals

Next Previous
Search
Drug Profile

Azacitidine/cedazuridine - Astex Pharmaceuticals

Alternative Names: ASTX-030

Latest Information Update: 12 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astex Pharmaceuticals
  • Developer Astex Pharmaceuticals; Otsuka Pharmaceutical
  • Class Antineoplastics; Aza compounds; Pyrimidine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action Antimetabolites; Cytidine deaminase inhibitors; DNA methylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 12 Dec 2024 Azacitidine/cedazuridine is still in phase-I development in Myelodysplastic-syndromes(First-line therapy) in Japan (PO, Tablet)
  • 09 Dec 2024 Efficacy, pharmacokinetic and adverse events data from a phase I trial in Myelodysplastic-syndromes released by Astex Pharmaceuticals
  • 07 Dec 2024 Pharmacokinetics, efficacy and adverse events data from phase I trial in Myelodysplastic syndromes presented at the at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top